Hydromorphone compared with diacetylmorphine for long-term opioid dependence

JAMA Psychiatry

Volumn 73, Issue 5, 2016, Pages 447-455

  Oviedo Joekes, Eugenia ^a,b   Guh, Daphne ^a   Brissette, Suzanne ^c   Marchand, Kirsten ^a,b   MacDonald, Scott ^d   Lock, Kurt ^a   Harrison, Scott ^d   Janmohamed, Amin ^a   Anis, Aslam H ^a,b   Krausz, Michael ^a,b   Marsh, David C ^e   Schechter, Martin T ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Providence Crosstown Clinic   (Canada)

^e NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; HYDROMORPHONE; METHADONE; STREET DRUG;

ADULT; ARTICLE; BRITISH COLUMBIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT DURATION; URINALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FOLLOW UP; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; SUBSTANCE ABUSE;

ADULT; BRITISH COLUMBIA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEROIN; HEROIN DEPENDENCE; HUMANS; HYDROMORPHONE; INJECTIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; LONG-TERM CARE; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; STREET DRUGS; SUBSTANCE ABUSE DETECTION;

EID: 84973333906     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2016.0109     Document Type: Article

References (36)

1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; 2: CD002207.
2. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; 2009 (3): CD002209.
3. Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015; 207 (1): 5-14.
4. Strang J, Groshkova T, Metrebian N, Strang J, Groshkova T, Metrebian N. New Heroin-Assisted Treatment: Recent Evidence and Current Practices of Supervised Injectable Heroin Treatment in Europe and Beyond. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2012.
5. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F; PEPSA team. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006; 31 (2): 203-211.
6. Demaret I, Quertemont E, Litran G, et al. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 2015; 21 (4): 179-187.
7. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009; 361 (8): 777-786.
8. Haasen C, Verthein U, Degkwitz P, Berger J, KrauszM, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007; 191 (191): 55-62.
9. van den BrinkW, Hendriks VM, Blanken P, KoeterMW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. [published correction appears in BMJ. 2003; 3217 (7417): 724]. BMJ. 2003; 327 (7410): 310.
10. Strang J, Metrebian N, Lintzeris N, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010; 375 (9729): 1885-1895.
11. Perneger TV, Giner F, del RioM, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 1998; 317 (7150): 13-18.
12. Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den BrinkW. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005; 330 (7503): 1297.
13. Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012; 184 (6): E317-E328. doi: 10.1503/cmaj.110669.
14. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2011; (12): CD003410.
15. Fletcher J. Canada in breach of ethical standards for clinical trials. CMAJ. 2014; 186 (1): 11.
16. Oviedo-Joekes E, Guh D, Brissette S, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010; 38 (4): 408-411.
17. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006; 145 (1): 62-69.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency. Subst Abuse Treat Prev Policy. 2015; 10: 3.
20. Oviedo-Joekes E, Marchand K, Guh D, et al. History of treatment access and drug use among participants in a trial testing injectable opioids under supervision for long-term heroin injectors. J Addict Med Ther. 2015; 3 (1): 1015-1026.
21. Laster LL, Johnson MF. Non-inferiority trials: the 'at least as good as' criterion. Stat Med. 2003; 22 (2): 187-200.
22. Oviedo-Joekes E, Marsh DC, Guh D, Brissette S, Schechter MT. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency. J Opioid Manag. 2011; 7 (5): 371-376.
23. Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998; 93 (12): 1857-1867.
24. Paterson S, Lintzeris N, Mitchell TB, Cordero R, Nestor L, Strang J. Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Addiction. 2005; 100 (12): 1832-1839.
25. Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014; 109 (4): 617-626.
26. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues: the encounters of academic consultants in statistics. Stat Med. 2003; 22 (2): 169-186.
27. Biering K, Hjollund NH, FrydenbergM. Using multiple imputation to deal with missing data and attrition in longitudinal studies with repeated measures of patient-reported outcomes. Clin Epidemiol. 2015; 7: 91-106.
28. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: disulfiramfor alcohol cessation-a VA cooperative study. Stat Med. 1996; 15 (13): 1421-1434.
29. Kullgren J, Le V, WheelerW. Incidence of hydromorphone-induced neuroexcitation in hospice patients. J Palliat Med. 2013; 16 (10): 1205-1209.
30. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med. 2011; 25 (5): 471-477.
31. Hong D, Flood P, Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth Analg. 2008; 107 (4): 1384-1389.
32. Chang AK, Bijur PE, Meyer RH, Kenny MK, Solorzano C, Gallagher EJ. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial. Ann Emerg Med. 2006; 48 (2): 164-172.
33. Gregory TB. Hydromorphone: evolving to meet the challenges of today's health care environment. Clin Ther. 2013; 35 (12): 2007-2027.
34. Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013; 75 (1): 60-78.
35. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012; 308 (24): 2594-2604.
36. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998; 51 (3): 253-263.